Why These 10 Large-Cap Stocks are Skyrocketing

1. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

30-day Return as of January 22, 2025: 51.7%

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a biopharmaceutical company that provides innovative treatments that improve the living conditions of individuals with neurological disorders. The stock surged by nearly 52% on January 22, going from $84 on December 22, 2024, to $127.41 within 30 days.

The biotech company saw a surge in its stock price after JNJ, the pharmaceutical giant, signed an agreement to acquire the stock for $14.6 billion, paying $132 per share on January 13, 2025. ITCI’s neurological lineup is expected to boost JNJ’s position in that department significantly.

In addition to that, ITCI was also favored among analysts due to its accelerated performance in drug development and approval. On January 12, BofA raised ITCI’s price target to $118 from $100 and kept a buy rating on the stock after the company announced its positive Caplyta patent settlement with Sandoz.

While we acknowledge the potential of ITCI to grow, our conviction lies in the belief that certain AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ITCI but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.